Estrella Immunopharma Inc (ESLA)

10:41 AM

How to integrate Estrella Immunopharma Inc. into portfolio analysis toolsPortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com

10:41 AM

05:56 AM

What data driven models say about Estrella Immunopharma Inc.’s futurePortfolio Risk Report & Free Fast Gain Swing Trade Alerts - newser.com

05:56 AM

Nov 06, 2025

Estrella Immunopharma Achieves Milestone in STARLIGHT-1 Trial - TipRanks

Nov 06, 2025

Nov 06, 2025

[8-K] Estrella Immunopharma, Inc. Reports Material Event | ESLA SEC FilingForm 8-K - Stock Titan

Nov 06, 2025

Nov 06, 2025

Is Estrella Immunopharma Inc. stock oversold or undervaluedQuarterly Market Summary & AI Enhanced Execution Alerts - newser.com

Nov 06, 2025

Nov 05, 2025

Is Estrella Immunopharma Inc. reversing from oversold territoryJuly 2025 Macro Moves & Advanced Technical Signal Analysis - newser.com

Nov 05, 2025

Nov 05, 2025

Is Estrella Immunopharma Inc. building a consolidation basePortfolio Value Report & AI Powered Buy/Sell Recommendations - newser.com

Nov 05, 2025

Nov 05, 2025

Is Estrella Immunopharma Inc. stock ready for breakoutJuly 2025 Institutional & Consistent Profit Alerts - newser.com

Nov 05, 2025

Nov 04, 2025

Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either? - Barchart.com

Nov 04, 2025

Nov 04, 2025

Estrella Immunopharma's (ESLA) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat

Nov 04, 2025

Nov 04, 2025

Check out these key findings about Estrella Immunopharma Inc (ESLA) - setenews.com

Nov 04, 2025

Nov 04, 2025

Using data models to predict Estrella Immunopharma Inc. stock movementQuarterly Trade Report & Reliable Momentum Entry Alerts - newser.com

Nov 04, 2025

Nov 04, 2025

Estrella Immunopharma (NASDAQ:ESLA) Given “Buy” Rating at D. Boral Capital - Defense World

Nov 04, 2025

Nov 04, 2025

Analyst Jason Kolbert Maintains Buy Rating on ESLA | ESLA Stock News - GuruFocus

Nov 04, 2025

Nov 03, 2025

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients - BioSpace

Nov 03, 2025

Nov 03, 2025

Estrella Immunopharma stock soars after 100% complete response rate in trial - Investing.com Australia

Nov 03, 2025

Nov 03, 2025

Is now a turning point for Estrella Immunopharma Inc.Quarterly Portfolio Summary & Growth-Oriented Investment Plans - newser.com

Nov 03, 2025

Nov 03, 2025

Estrella Immunopharma, Inc. (ESLA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK

Nov 03, 2025

Nov 03, 2025

Will Estrella Immunopharma Inc. stock gain from government policiesSell Signal & Weekly Return Optimization Plans - newser.com

Nov 03, 2025

Nov 03, 2025

What indicators show strength in Estrella Immunopharma Inc.2025 Valuation Update & Daily Chart Pattern Signals - newser.com

Nov 03, 2025

Nov 03, 2025

Leading vs lagging indicators on Estrella Immunopharma Inc. performanceLayoff News & Safe Entry Point Alerts - newser.com

Nov 03, 2025

Nov 01, 2025

Estrella Immunopharma (NASDAQ:ESLA) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat

Nov 01, 2025

Nov 01, 2025

Estrella Immunopharma, Inc. (ESLA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Nov 01, 2025